Current UK MPN trials

Essential thrombocythaemia (ET) and polycythaemia vera (PV)

TAMARIN evaluating the role of Tamoxifen in combination with standard therapy is now open.

The aim of this study is to assess whether giving tamoxifen to patients receiving therapy for their MPN reduces the number of mutated cells found in the blood by ≥ 50% after 24 weeks of treatment compared to the start of the study.

For further details of this study, including inclusion and exclusion criteria click here...
Study end date: September 2017

 
GIVINOSTAT currently being evaluated in patients with PV.

For further details of this study, including inclusion and exclusion criteria click here...
Study end date: June 2020
 

MF

TAMARIN evaluating the role of Tamoxifen in combination with standard therapy is now open.

The aim of this study is to assess whether giving tamoxifen to patients receiving therapy for their MPN reduces the number of mutated cells found in the blood by ≥ 50% after 24 weeks of treatment compared to the start of the study.

For further details of this study, including inclusion and exclusion criteria click here...
Study end date: September 2017


STUDY OF THE SAFETY OF PIM447 in combination with Ruxolitinib (INC424) and LEE011 in patients with Myelofibrosis.
  
For further details of this study, including inclusion and exclusion criteria click here…
Study end date: September 2017
 

PATIENTS WITH AGGRESSIVE MPN or leukaemia after MPN

PHAZAR – a study for patients developing leukaemia after MPN or patients whose disease is close to leukaemia is currently open in 13 centres. This study is assessing the role of combining a standard leukaemia drug azacytidine with Ruxolitinib.

For further details of this study, including inclusion and exclusion criteria click here...
 

Study Data

We are currently awaiting data from a large number of studies that were open including:

SIMPLIFY 1 & 2
IMBARK
PROMOTE

Results will be published when they are available

 

SYMPTOM ASSESSMENT

THE MEASURES STUDY a symptom assessment study is open in over 20 centres in the UK.

Myeloproliferative neoplasms (MPNs) are associated with a range of symptoms that can affect many different systems of the body. We have developed a diary designed to record the impact of symptoms in patients with MPNs. It is based on a previously tested questionnaire, the MPN symptom assessment form (MPN-SAF). This study aims to test the diary to see if it is effective at recording the impact of patients symptoms.

 To read more about this study click here... 
 

SAMPLE BANKS

Studies with banks in Cambridge, Salisbury, Oxford and Guy’s Hospital are open.

The project will sequence 100,000 genomes from around 70,000 people. Participants are NHS patients with a rare disease, plus their families, and patients with cancer, MPNs are included in the 100k genome project. 

The aim is to create a new genomic medicine service for the NHS – transforming the way people are cared for. Patients may be offered a diagnosis where there wasn’t one before. In time, there is the potential of new and more effective treatments.
 
For further details of this study click here...
 

Useful websites

Visit any of these websites to find more information about trials.


If you are interested in enrolling in a trial and live in the U.K. please email us at info@mpnvoice.org.uk for details of the centres/hospitals running the trials, please tell us where you live and which hospital you attend. If you live outside the U.K. please contact your haematologist for details.

In the United States

You can learn more about trials from several organisations in the United States.

  • MPN Research Foundation (US) The MPN Research Foundation (US) raises funds for MPD research and reports on clinical trials, press releases from biotech and pharmaceutical companies and the latest discoveries.
  • NIH The National Institutes of Health In the US offers detailed and accurate information on diseases and a search tool to find clinical trials internationally.
  • NCI The National Cancer Institute (NCI)’s clinical trials page offers detailed information on trials taking place in the UK and US – search by disease name, for instance “myelofibrosis”.

You can also watch the video interview of Albert, who enrolled on a JAK2 inhibitor trial. You can read about people who are taking the newest drugs in Real Stories.